Vaishali Pharma

Mumbai, India Founded: 1989 • Age: 37 yrs Listed
Finished formulations, APIs, and intermediates are manufactured.
Request Access
Report Incorrect Data
Page last updated

About Vaishali Pharma

Vaishali Pharma is a publicly listed company based in Mumbai (India) founded in 1989. Finished formulations, APIs, and intermediates are manufactured. The company has 15 employees. Vaishali Pharma has completed 1 acquisition, including Kesar Pharma. Its chief executive, as recorded, is Anil Lakhan. Its Indian entity Vaishali Pharma Limited reported revenue of ₹113 Cr. Vaishali Pharma offers products and services including API, Formulations, Surgical Products, Herbal Products, and Veterinary Products. Its focus areas include Biopharma Outsourcing, CDMO and Small Molecules & Peptides. Similar companies include Indoco Remedies, Concord Biotech and BDR Pharmaceuticals Internationals; 1 of its 3 listed similar companies has raised funding.

Company details

Vaishali Pharma was established in 1989 in Mumbai, India, within the pharmaceutical sector. Operations focus on producing finished formulations including tablets, capsules, syrups, semi-solids, and injectables. APIs, intermediates, and veterinary products are also manufactured. Therapeutic categories addressed include antibiotics, antiplatelet agents, antiulcer drugs, laxatives, anticold remedies, antimalarials, and additional areas.

  • Headquarters Mumbai, India
  • Employees 15
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website vaishalipharma.com
  • Social LinkedIn X Facebook Instagram
  • Legal Name Vaishali Pharma Ltd.
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹92.75 Cr

    VAISHALI · NSE

  • Share Price
    ₹6.85

    -0.29% today

  • Revenue
    ₹109 Cr

    FY 2025-26 · +9.8% YoY

  • EBITDA
    ₹4.11 Cr

    Margin 3.8%

  • Net Profit
    ₹4.03 Cr

    FY 2025-26 · +391.5% YoY

  • P/E (TTM)
    20.8x

    P/B 1.2x

  • Employee Count
    15
  • Investments & Acquisitions
    Kesar Pharma

Products & Services of Vaishali Pharma

Vaishali Pharma offers a comprehensive portfolio of products and services, including API, Formulations, Surgical Products, Herbal Products, and Veterinary Products.

API
Pharmaceutical Ingredients

Active ingredients for therapeutic drug effects

Formulations
Finished Pharmaceuticals

Various dosage forms for multiple therapies

Surgical Products
Medical Supplies

High-performance items for hospital use

Herbal Products
Natural Remedies

Plant-based supplements for health care

Veterinary Products
Animal Health

Medications for affordable animal care

Nutraceutical Products
Dietary Supplements

Vitamins and minerals for daily health

Oncology Products
Cancer Treatment

Specialized drugs for cancer diagnosis and therapy

Board of directors of Vaishali Pharma Limited (Vaishali Pharma)

Vaishali Pharma Limited is the primary company behind Vaishali Pharma. The board of Vaishali Pharma Limited currently have 5 directors; the longest-serving is Atul Arvind Vasani, appointed in 2008. 9 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Atul Arvind Vasani
DIN 02107085
Managing Director25 Apr 200818 yrs 6 moVaishali Pharma Limited
Jagruti Atul Vasani
DIN 02107094
Whole-time director12 Nov 200916 yrs 11 moVaishali Pharma Limited
Dewansh Ajay Vasani
DIN 08111804
Director26 Apr 20188 yrs 6 moVaishali Pharma Limited
Manish Bhagwandas Ved
DIN 08654674
Director31 Dec 20196 yrs 9 moVaishali Pharma Limited
Pratik Vikram Jakhelia
DIN 07726752
Director10 Jul 20215 yrs 3 moVaishali Pharma Limited

People of Vaishali Pharma

2 people are tracked at Vaishali Pharma (2 in leadership); the tracked headcount is 15.

NameRoleGroup
Anil Lakhan
CEOLeadership
Hemant Damodar Pathak
Chief Executive OfficerLeadership
Premium access

Complete people profiles for Vaishali Pharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Vaishali Pharma

Vaishali Pharma is a publicly listed company on the NSE with ticker symbol VAISHALI in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date15 Jan 2020
  • Listed onNSE: VAISHALI
  • Listed entityVaishali Pharma Ltd.
  • Exchange sectorHealth technology
  • ISININE972X01022
  • Share price₹7.95 (-0.38% on the day) · 2026-10-14
  • Market capitalisation₹85.5 Cr
  • Price to earnings24.2
  • EPS (diluted, trailing year)₹0.33
  • Volume (last session)39,673

Financials of Vaishali Pharma

Exchange-reported figures of Vaishali Pharma Limited, the listed company behind Vaishali Pharma (NSE: VAISHALI).

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹109 Cr
+9.8% YoY
EBITDA
₹4.11 Cr
+608.6% YoY
Profit After Tax
₹4.03 Cr
+391.5% YoY
Net Worth
₹68.98 Cr
+6.3% YoY
Total Assets
₹88.16 Cr
+13.8% YoY
Total Debt
₹18.89 Cr
+53.3% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue10999.0386.2869.6675.8253.7760.09
Revenue growth+9.8%+14.8%+23.9%-8.1%+41.0%-10.5%-
EBITDA4.110.581.679.386.882.650.90
EBITDA margin+3.8%+0.6%+1.9%+13.5%+9.1%+4.9%+1.5%
Profit before tax5.391.230.928.855.721.400.07
Net profit4.030.820.716.614.021.040.02
Net profit margin+3.7%+0.8%+0.8%+9.5%+5.3%+1.9%+0.0%
EPS (₹)0.310.060.676.263.820.990.03
Balance sheet
Total assets88.1677.4956.5355.4647.3540.4538.56
Net worth68.9864.9142.8540.5426.3622.4221.39
Total debt18.8912.3213.4914.7320.8117.8517.04
Cash & bank1.431.841.580.981.360.470.38
Net working capital77.8672.1451.1049.2342.1735.6333.58
Cash flow
Cash from operations0.31(18.04)0.811.081.322.013.22
Cash from investing(5.33)(0.20)1.200.28(0.85)(0.11)(0.02)
Cash from financing4.6118.50(1.42)(1.73)0.42(1.81)(3.14)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue22.8926.9324.6533.4523.7532.2527.9120.79
Revenue growth (YoY)-3.6%-16.5%-11.7%+60.9%+31.4%---
Other income0.581.260.890.840.841.001.070.71
Total expenses21.4127.1323.0932.0622.3838.2926.5518.37
EBITDA1.48(0.20)1.561.391.37(6.04)1.362.42
EBITDA margin+6.5%-0.7%+6.3%+4.2%+5.8%-18.7%+4.9%+11.6%
Depreciation0.140.160.130.170.140.120.120.12
Interest0.200.720.510.400.330.440.380.38
Profit before tax1.720.181.811.661.74(5.60)1.932.63
Tax0.24(0.09)0.510.470.46(1.31)0.480.66

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 26 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue22.8926.9324.6533.4523.7532.2527.9120.79
Revenue growth (YoY)-3.6%-16.5%-11.7%+60.9%+31.4%---
Other income0.581.260.890.840.841.001.070.71
Total expenses21.4127.1323.0932.0622.3838.2926.5518.37
EBITDA1.48(0.20)1.561.391.37(6.04)1.362.42
EBITDA margin+6.5%-0.7%+6.3%+4.2%+5.8%-18.7%+4.9%+11.6%
Depreciation0.140.160.130.170.140.120.120.12
Interest0.200.720.510.400.330.440.380.38
Profit before tax1.720.181.811.661.74(5.60)1.932.63
Tax0.24(0.09)0.510.470.46(1.31)0.480.66
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue10999.0386.2869.6675.8253.7760.09
Revenue growth+9.8%+14.8%+23.9%-8.1%+41.0%-10.5%-
Other income3.843.212.032.231.791.812.17
Total expenses10598.4584.6160.2868.9451.1259.19
Employee cost0.001.581.401.301.361.191.27
EBITDA4.110.581.679.386.882.650.90
EBITDA margin+3.8%+0.6%+1.9%+13.5%+9.1%+4.9%+1.5%
Depreciation0.600.490.510.500.460.430.44
Interest1.962.072.272.262.492.632.56
Profit before tax5.391.230.928.855.721.400.07
Tax1.360.410.212.241.700.360.05
Net profit4.030.820.716.614.021.040.02
Net profit margin+3.7%+0.8%+0.8%+9.5%+5.3%+1.9%+0.0%
EPS (₹)0.310.060.676.263.820.990.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital26.0926.0910.7210.5510.5510.5510.55
Reserves & surplus42.8938.8225.1029.9915.8111.8710.84
Shareholders' funds (net worth)68.9864.9142.8540.5426.3622.4221.39
Secured loans18.5011.6412.0713.0015.0317.3016.28
Unsecured loans0.390.681.421.735.780.550.76
Total debt18.8912.3213.4914.7320.8117.8517.04
Total liabilities88.1677.4956.5355.4647.3540.4538.56
Assets
Gross block5.164.713.893.853.302.892.73
Net block1.691.841.521.991.181.221.49
Capital work in progress0.250.250.740.670.490.050.08
Investments5.430.430.430.430.430.430.43
Inventories3.404.810.383.050.630.590.88
Sundry debtors50.7746.7249.4353.6158.5166.7347.03
Cash & bank balances1.431.841.580.981.360.470.38
Loans & advances57.3651.1223.1415.0315.9413.5112.93
Total current assets11310474.5372.6776.4481.3061.22
Total current liabilities35.1032.3523.4323.4434.2745.6727.64
Net working capital77.8672.1451.1049.2342.1735.6333.58
Total assets88.1677.4956.5355.4647.3540.4538.56
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1.841.580.981.360.470.380.32
Net cash from operating activities0.31(18.04)0.811.081.322.013.22
Net cash from investing activities(5.33)(0.20)1.200.28(0.85)(0.11)(0.02)
Net cash from financing activities4.6118.50(1.42)(1.73)0.42(1.81)(3.14)
Net change in cash(0.41)0.260.59(0.37)0.890.090.06
Closing cash1.431.841.580.981.360.470.38
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+9.8%+14.8%+23.9%-8.1%+41.0%-10.5%-
EBITDA growth+608.6%-65.3%-82.2%+36.3%+159.6%+194.4%-
PBT growth+338.2%+33.7%-89.6%+54.7%+308.6%+1900.0%-93.8%
Net income growth+391.5%+15.5%-89.3%+64.4%+286.5%+5100.0%-
Revenue CAGR (3Y)+16.0%+9.3%+17.1%+5.1%+0.3%-7.4%-2.1%
EBITDA CAGR (3Y)-24.1%-56.2%-14.3%+118.4%+49.2%-1.6%-36.2%
Profitability & leverage
Net income margin+3.7%+0.8%+0.8%+9.5%+5.3%+1.9%+0.0%
Return on capital employed-+4.9%+5.7%+21.6%+18.7%+10.2%+6.8%
Return on net worth-+1.5%+1.7%+19.7%+16.5%+4.8%+0.1%
Debt / equity-0.240.340.530.790.800.80
Long-term debt / equity-0.090.140.160.210.250.25
Interest cover55.842,300.00195.6925.4538.79118.47556.52
Efficiency & per share
Fixed asset turnover-23.0822.2919.4924.5019.1424.68
Inventory turnover-38.1650.3137.86124.3073.1664.61
Debtors turnover-2.061.671.241.210.951.25
EPS (₹)0.310.060.676.263.820.990.03
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.004.9833.4138.4324.9921.2620.27

Investments & Acquisitions by Vaishali Pharma

Vaishali Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Kesar Pharma.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Kesar Pharma
Pharmaceutical finished formulations including tablets and capsules are manufactured.
kesarpharma.comAhmedabad, India1994Feb 2025$2.45M
Premium access

Complete acquisition details for Vaishali Pharma

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Vaishali Pharma

3 dated milestones of Vaishali Pharma across 36 years, from founding to its latest funding, stage changes and deals.

  1. Founded Vaishali Pharma is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Acquisition Acquires Kesar Pharma.

Similar companies to Vaishali Pharma

Vaishali Pharma has 3 listed similar companies in our database, 1 of them funded. They include Indoco Remedies, Concord Biotech and BDR Pharmaceuticals Internationals.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Indoco Remedies
indoco.com1947Mumbai, India6,291
APIs manufacturing and formulation services are provided in therapeutic segments.
Concord Biotech
concordbiotech.com2000Ahmedabad, India1,598
APIs and enzymes are manufactured through fermentation by the CDMO.
BDR Pharmaceuticals Internationals
bdrpharma.com2003Mumbai, India$88.16M1,864
APIs and finished products are developed and manufactured.
Premium access

Detailed similar companies of Vaishali Pharma

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Vaishali Pharma

The website of Vaishali Pharma (vaishalipharma.com) receives about 1.5K visits a month and ranks #11,147,670 among all websites worldwide, #8,057 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    1.5K

    ▲ 30.1% vs previous month

  • Global rank
    #11,147,670

    among all websites

  • Category rank
    #8,057

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Vaishali Pharma. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
tajpharma.com
tajpharma.com
100%
#2,930,852–
Yash Pharma
yashpharma.com
78%
View details
pharmexcil.org
pharmexcil.org
78%
–
lotusinternational.com
lotusinternational.com
74%
#6,298,265–
lotuscentre.ac.in
lotuscentre.ac.in
30%
#8,518,322–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 12 similar websites and full traffic analytics for Vaishali Pharma

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 12 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Vaishali Pharma (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M1,820
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M12,470
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M4,260
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Vaishali Pharma

Vaishali Pharma standalone net profit rises 16.41% in the June 2026 quarter | Capital Market News - Business Standard
Business Standard • 2 months ago
VAISHALI: Q1 FY27 net profit rose to ₹148.97 lakh standalone, with consolidation of Kesar Pharma boosting group results
Quartr • 2 months ago
Vaishali Pharma Defers Proposal To Issue Equity Shares
Reuters • 3 months ago
VAISHALI: Strong revenue and profit growth, with new associate consolidation and auditor caution on receivables
Quartr • 5 months ago
VAISHALI: Net profit after tax surged to ₹403.17 lakhs on revenue of ₹10,877.23 lakhs in FY 2025-26
Quartr • 5 months ago
Vaishali Pharma Approved Issue Of Shares Of Up To 122.5 Million Rupees
Reuters • 8 months ago
VAISHALI: Q3 FY26 profit rose sequentially, preferential issue to raise ₹12.25 crore approved
Quartr • 8 months ago
VAISHALI: Strong revenue and profit growth with improved margins and positive operating cash flow
Quartr • 11 months ago
VAISHALI: Revenue increased but net profit and EPS declined year-over-year for Q1 FY26
Quartr • 1 year ago
VAISHALI: Q1 FY26 saw higher revenue but lower net profit and EPS amid rising expenses
Quartr • 1 year ago
Premium access

Complete news archive for Vaishali Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Vaishali Pharma

Vaishali Pharma was founded in 1989.

Vaishali Pharma is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Anil Lakhan is the CEO of Vaishali Pharma, as recorded in our data.

Vaishali Pharma has 15 employees.

The primary company behind Vaishali Pharma, Vaishali Pharma Limited, reported revenue of ₹113 Cr for FY 2026, up 10% year on year.

Vaishali Pharma was established in 1989 in Mumbai, India, within the pharmaceutical sector. Operations focus on producing finished formulations including tablets, capsules, syrups, semi-solids, and injectables. APIs, intermediates, and veterinary products are also manufactured. Therapeutic categories addressed include antibiotics, antiplatelet agents, antiulcer drugs, laxatives, anticold remedies, antimalarials, and additional areas.

Vaishali Pharma's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Indoco Remedies.

Vaishali Pharma offers API, Formulations, Surgical Products, Herbal Products, and 3 more products and services.

Yes, Vaishali Pharma is publicly traded on NSE under the ticker symbol VAISHALI.

Vaishali Pharma has made 1 acquisition, including Kesar Pharma.

Vaishali Pharma operates through Vaishali Pharma Limited.

The legal entities of Vaishali Pharma currently have 7 directors, including Atul Arvind Vasani, Jagruti Atul Vasani, Dewansh Ajay Vasani and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available